Ticagrelor for acute coronary syndrome?

Drug and Therapeutics Bulletin

Volumn 49, Issue 6, 2011, Pages 66-68

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATININE; ERGOT ALKALOID; KETOCONAZOLE; MEVINOLIN; PRASUGREL; SIMVASTATIN; TICAGRELOR; URIC ACID;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; URIC ACID BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ADENOSINE; DRUG COSTS; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79958222142     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2011.02.0035     Document Type: Article

References (20)

1. National Institute for Health and Clinical Excellence, 2009. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. Technology appraisal guidance 182 [online]. Available: http://guidance.nice.org.uk/TA182/Guidance/pdf/English [Accessed 19 May 2011].
2. 2010 National Clinical Guideline Centre. Unstable angina and NSTEMI. The early management of unstable angina and non-ST-segment-elevation myocardial infarction. Clinical guideline 94 [online]. Available: http://www.nice.org.uk/nicemedia/live/12949/47988/47988.pdf [Accessed 19 May 2011].
3. 2011 Joint Formulary Committee. British National Formulary. Edition 61. London: BMJ Group and Pharmaceutical Press, March.
4. 2010 Brilique 90mg film coated tablets. Summary of product characteristics, EU. AstraZeneca, December.
5. Fox KAA et al. 2006 Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 333: 1091.
6. 2010 Price, pragmatism and prasugrel. DTB 48, 121.
7. Marczewski MM et al. 2010 Novel antiplatelet agents in the prevention of cardiovascular complications - focus on ticagrelor. Vasc Health Risk Manag 6: 419-29.
8. 2002 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
9. Yusuf S et al. 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502.
10. Wiviott SD et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-15.
11. Cannon CP et al. 2010 Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375: 283-93.
12. Cannon CP et al. 2007 Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol; 50: 1844-51.
13. Wallentin L et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-57.
14. Steg PG et al. 2010 Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122: 2131-41.
15. James S et al. 2010 Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 31: 3006-16.
16. James S et al. 2010 Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122: 1056-67.
17. Biondi-Zoccai G et al. 2010 Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol [Epub ahead of print]; doi:10.1016/j.ijcard.2010.08.035.
18. Serebruany VL. 2010 The TRITON versus PLATO trials: differences beyond platelet inhibition. Thromb Haemost 103: 259-61.
19. Regional Drug and Therapeutics Centre, 2011. New drug evaluation. Ticagrelor [online]. Available: http://www.nyrdtc.nhs.uk/docs/nde/NDE_109_Ticagrelor.pdf [Accessed 19 May 2011].
20. Scottish Medicines Consortium, 2011. Ticagrelor 90mg film-coated tablets (Brilique): SMC No. 699/11 [online]. Available: http://www.scottishmedicines.org.uk/files/advice/ticagrelor_Brilique_FINAL_APRIL_2011_amended_030511_for_website.pdf [Accessed 19 May 2011].